目錄:MedChemExpress LLC>>生化試劑>> Concizumab | MCE
CAS | 1312299-39-0 | 供貨周期 | 現(xiàn)貨 |
---|---|---|---|
規(guī)格 | 5 mg | 貨號 | HY-P99283 |
應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
CAS No. : 1312299-39-0
產(chǎn)品活性:Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
研究領(lǐng)域:Others
作用靶點:Others
In Vitro: Concizumab increases thrombin peak in a concentration- dependent manner.
In Vivo: Concizumab (i.v./s.c.) blocks the TFPI interaction with the active site of FXa in cynomolgus monkeys.
Parameter | Unit | Estimate | %RSE |
CLL | mL/h/kg | 0.14 | 6.1 |
V1 | mL/kg | 33 | 34 |
V2 | mL/kg | 33 | - |
Q | mL/h/kg | 0.12 | 16 |
F | % | 93 | 7.7 |
Vmax | µg/h/kg | 11 | 17 |
Km | µg/mL | 0.54 | 52 |
t1/2(abs) | h | 72 | 32 |